Aspira Women's Health Welcomes Ellen Beausang to Its Board of Directors

• Aspira Women's Health appoints Ellen Beausang to its Board of Directors on February 10, 2025.
• Beausang serves as Chief Commercial Officer at BioReference Health.
• Appointment aligns with a commercial inflection point for the company.

Aspira Women's Health (NASDAQ:AWH) has appointed Ellen Beausang to its Board of Directors, effective February 10, 2025. Beausang, the Chief Commercial Officer at BioReference Health, brings extensive expertise in commercial strategy within the diagnostics sector. Her appointment comes at a pivotal time for the company as it seeks to expand its market presence by growing existing business lines and developing new diagnostic tests.

Beausang has over five years of experience at BioReference Health. Held executive positions at major healthcare companies, including Pfizer, Thermo Fisher Diagnostics, and Quest Diagnostics.

CEO Michael Buhle emphasized her expertise as a key asset for accelerating business growth. Expected to play a vital role in advancing Aspira Women's Health's mission in women's healthcare.

"We are pleased to welcome Ellen Beausang to the Board of Directors," said Michael Buhle, Chief Executive Officer of Aspira Women's Health. "Ellen brings a proven track record of developing and executing successful commercial strategies in the diagnostics sector. Her expertise comes at a pivotal time for Aspira Women's Health as we expand our current business lines and develop new diagnostic tests to enhance our market presence. Her leadership will be instrumental in driving our growth and advancing our mission to transform women's healthcare."

Ellen was previously in an executive role at BioReference Health, a provider of innovative and tailored laboratory test solutions, for over five years. She has held the role of Chief Commercial Officer since 2022.

Prior to this, she held executive roles of increasing responsibility at leading pharmaceutical and diagnostic companies, including, Pfizer, Thermo Fisher Diagnostics and Quest Diagnostics.